{Reference Type}: Journal Article
{Title}: Self-reported outcomes and quality of life of patients with non-dystrophic myotonia: The French IMPACT 2022 survey.
{Author}: Vicart S;Péréon Y;Ghorab K;Pegat A;Dufresne R;Zozulya-Weidenfeller A;Noury JB;Nadaj-Pakleza A;Tard C;Sacconi S;
{Journal}: Rev Neurol (Paris)
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 28
{Factor}: 4.313
{DOI}: 10.1016/j.neurol.2024.04.007
{Abstract}: Non-dystrophic myotonias (NDM) are disabling genetic diseases that impact quality of life. To reduce the impact of NDM, patients develop coping strategies such as lifestyle adaptation and avoiding key triggers. To understand how myotonia affects patients' lives, the IMPACT survey, an online questionnaire on patient-reported outcomes, was developed based on international IMPACT questionnaire. The French IMPACT 2022 survey was completed by 47 NDM French patients. Besides muscle stiffness (98%), patients reported muscle pain (83%), falls (70%) and anxiety (77%). These issues negatively impacted abilities to work/study (49%), daily life at home (49%) and overall mobility outside (49%). Most patients (96%) reported ongoing pharmacological treatment (mexiletine, 91%) associated with improvement in muscle stiffness (100%) and reduction in falls (94%), muscle pain (87%) and anxiety (80%). Patients were moderately satisfied (19.1%), satisfied (42.6%) and very satisfied (29.8%) with the current management; 32% rated their quality of life positively (≥ 8 on 10-point scale). In conclusion, this French survey confirms the impact of myotonia on daily life and quality of life. The improvement in patient-reported outcomes in treated participants highlights the importance of managing myotonia with effective treatments. More work should be initiated to assess the importance of NDM symptom management and patients' adherence and compliance to treatment.